Senseera – a liquid biopsy company pioneering chromatin epigenomics – announced closing a $7.1 million seed funding round led by Lightspeed Venture Partners, with participation from I-Next Capital and the Lowy Medical Research Institute.
This funding will advance Senseera’s GEM BIOMARKERS liquid biopsy platform (powered by cfChIP-seq technology). This platform decodes cell-specific gene expression and cell states from a simple blood draw, providing detailed molecular insights for diagnosing and monitoring diseases. And this transformative approach delivers the precision of biopsy-level insights with the convenience of a non-invasive blood test.
Senseera’s technology is built on several decades of research led by Prof. Nir Friedman and validated in top-tier journals such as Nature Biotechnology. Supported by data from 20,000+ human samples, Senseera has established a robust foundation for accelerating drug development and precision medicine in oncology, immunology, and metabolic diseases and transforming liver disease management.
Liver diseases represent a major global health challenge, affecting up to 25% of the population. And existing diagnostics often rely on invasive and risky biopsies or non-specific tests, resulting in delayed diagnoses and suboptimal patient care.
Senseera’s platform provides an innovative solution for early detection and management of conditions like MASLD/MASH, liver transplant rejection, and hepatocellular carcinoma (HCC). These funds will accelerate market entry for Senseera’s next-generation transplant rejection test, advance clinical trials, and expand partnerships with global biopharma.
Along with its unique liver diseases diagnostics pipeline, Senseera’s platform offers unparalleled potential for accelerating drug development in cancer and immune disorders. And by providing simultaneous solid tissue and immune cell states monitoring, the platform provides insights into tissue/tumor immune cross-talk, enabling researchers and clinicians to understand the underlying mechanisms better and support personalized treatments.
KEY QUOTE:
“This funding marks a major milestone in Senseera’s journey to transform diagnostics for liver diseases and beyond, and to accelerate drug development. With the support from Lightspeed and our investors, we will advance clinical trials, strengthen collaborations with global pharma leaders, and expand our pipeline to improve patient outcomes.”
– Dr. Ronen Sadeh, CEO of Senseera
